# Hypofractionated Brain Radiation In EGFR Mutated Adenocarcinoma Cranial Disease (Hybrid)

> **NCT02882984** · PHASE3 · UNKNOWN · sponsor: **Sichuan Provincial People's Hospital** · enrollment: 325 (estimated)

## Conditions studied

- Stage IV EGFR Mutated NSCL With Brain Metastases

## Interventions

- **DRUG:** Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid Other Name: Gefitinib/Tarceva/Icotinib
- **RADIATION:** WBRT
- **RADIATION:** HFSRS

## Key facts

- **NCT ID:** NCT02882984
- **Lead sponsor:** Sichuan Provincial People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-03
- **Primary completion:** 2020-03
- **Final completion:** 2020-12
- **Target enrollment:** 325 (ESTIMATED)
- **Last updated:** 2016-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02882984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02882984, "Hypofractionated Brain Radiation In EGFR Mutated Adenocarcinoma Cranial Disease (Hybrid)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02882984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*